randomisation sequence (EPS Corporation)
90
Structured Review
EPS Corporation
randomisation sequence
Randomisation Sequence, supplied by EPS Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomised+sequences/randomisation+sequence/pmc06483552-574-8-13
Average 90 stars, based on 1 article reviews
Randomisation Sequence, supplied by EPS Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomised+sequences/randomisation+sequence/pmc06483552-574-8-13
Average 90 stars, based on 1 article reviews
randomisation sequence - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Chemotherapy for advanced gastric cancer"
Article Title: Chemotherapy for advanced gastric cancer
Journal: The Cochrane Database of Systematic Reviews
doi: 10.1002/14651858.CD004064.pub4
Figure Legend Snippet: Ajani 2010
Techniques Used: Sequencing, Selection
Figure Legend Snippet: Al‐Batran 2013
Techniques Used: Biomarker Discovery, Sequencing, Selection
Figure Legend Snippet: Barone 1998
Techniques Used: Control, Sequencing, Selection
Figure Legend Snippet: Bouche 2004
Techniques Used: Adjuvant, Sequencing, Selection
Figure Legend Snippet: Dank 2008
Techniques Used: Adjuvant, Sequencing, Selection
Figure Legend Snippet: Hironaka 2016
Techniques Used: Control, Sequencing, Selection, Generated
Figure Legend Snippet: Huang 2013
Techniques Used: Sequencing, Selection
Figure Legend Snippet: Lutz 2007
Techniques Used: Sequencing, Selection, Computed Tomography
Figure Legend Snippet: Nishikawa 2012
Techniques Used: Sequencing, Selection
Figure Legend Snippet: Ocvirk 2012
Techniques Used: Biomarker Discovery, Sequencing, Selection
Figure Legend Snippet: Roth 2007
Techniques Used: Biomarker Discovery, Sequencing, Selection
Figure Legend Snippet: Yamada 2015
Techniques Used: Sequencing, Selection, Generated, Expressing
Figure Legend Snippet: NCT02076594
Techniques Used: Biomarker Discovery, Control
Figure Legend Snippet: NCT03006432
Techniques Used:
Related Articles
Selection:Article Title: Chemotherapy for advanced gastric cancer Article Snippet: Random sequence generation (selection bias) , Low risk , Randomisation was done centrally with the minimisation method using performance status (0 vs 1) and tumour stage (stage IV vs recurrent) as stratification factors. .. Allocation concealment (selection bias) , Low risk , Sequencing:Article Title: Chemotherapy for advanced gastric cancer Article Snippet: Random sequence generation (selection bias) , Low risk , Randomisation was done centrally with the minimisation method using performance status (0 vs 1) and tumour stage (stage IV vs recurrent) as stratification factors. .. Allocation concealment (selection bias) , Low risk , Article Title: S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial Article Snippet: Methods In this multicentre, randomised, open-label, phase 2 trial, we recruited chemotherapy-naive patients with unresectable or recurrent gastric cancer with measurable lesions aged 20 years or older from 25 general hospitals and specialist centres in Japan.. Patients were randomly assigned (1:1:1) centrally to receive S-1 plus leucovorin (S-1 40–60 mg orally plus oral leucovorin 25 mg twice a day for 1 week, every 2 weeks), S-1 plus leucovorin and oxaliplatin (S-1 plus leucovorin and intravenous oxaliplatin 85 mg/m2 on day 1, every 2 weeks), or S-1 plus cisplatin (S-1 40–60 mg orally twice a day for 3 weeks, plus intravenous cisplatin 60 mg/m2 on day 8, every 5 weeks).. Randomisation was done with the minimisation method using performance status (0 vs 1) and tumour stage (stage IV vs recurrent) as stratifi cation factors. Generated:Article Title: Chemotherapy for advanced gastric cancer Article Snippet: Random sequence generation (selection bias) , Low risk , Randomisation was done centrally with the minimisation method using performance status (0 vs 1) and tumour stage (stage IV vs recurrent) as stratification factors. .. Allocation concealment (selection bias) , Low risk , Article Title: S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial Article Snippet: Methods In this multicentre, randomised, open-label, phase 2 trial, we recruited chemotherapy-naive patients with unresectable or recurrent gastric cancer with measurable lesions aged 20 years or older from 25 general hospitals and specialist centres in Japan.. Patients were randomly assigned (1:1:1) centrally to receive S-1 plus leucovorin (S-1 40–60 mg orally plus oral leucovorin 25 mg twice a day for 1 week, every 2 weeks), S-1 plus leucovorin and oxaliplatin (S-1 plus leucovorin and intravenous oxaliplatin 85 mg/m2 on day 1, every 2 weeks), or S-1 plus cisplatin (S-1 40–60 mg orally twice a day for 3 weeks, plus intravenous cisplatin 60 mg/m2 on day 8, every 5 weeks).. Randomisation was done with the minimisation method using performance status (0 vs 1) and tumour stage (stage IV vs recurrent) as stratifi cation factors. |
Guillaumier 2018 " width="250" height="auto" />
Holliday 2019 " width="100%" height="100%">
Skelton 2022 " width="100%" height="100%">